Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
NCT04736420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78605
Last updated 2023-07-28
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Venous Thromboembolism
Interventions
- DRUG
-
Rivaroxaban
Rivaroxaban dispensing claim is used as the exposure group
- DRUG
-
Warfarin
Warfarin dispensing claim is used as the reference group
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-22
- Primary Completion
- 2021-02-18
- Completion
- 2021-02-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
NCT05264168 ·Status: COMPLETED
-
Treatment for Blood Clots in the Veins of the Legs
NCT00001713 ·Status: COMPLETED ·Phase: PHASE1
-
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
NCT00439725 ·Status: COMPLETED ·Phase: PHASE3
-
Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
NCT02123524 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
NCT00440193 ·Status: COMPLETED ·Phase: PHASE3
-
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
NCT00786422 ·Status: COMPLETED ·Phase: PHASE2
-
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
NCT02064439 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
NCT00643201 ·Status: COMPLETED ·Phase: PHASE3
-
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
NCT03404635 ·Status: COMPLETED
-
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
NCT02111564 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
NCT05795062 ·Status: COMPLETED
-
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
NCT02555878 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
NCT00680186 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04263038 ·Status: RECRUITING ·Phase: PHASE4
-
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
NCT05920343 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
NCT03413618 ·Status: COMPLETED ·Phase: PHASE4
-
Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs
NCT00311090 ·Status: COMPLETED ·Phase: PHASE3
-
Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant
NCT02079584 ·Status: COMPLETED
-
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
NCT00439777 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
NCT03266783 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
NCT06965998 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
NCT00291330 ·Status: COMPLETED ·Phase: PHASE3
-
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
NCT06232551 ·Status: RECRUITING ·Phase: NA
-
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
NCT02161731 ·Status: COMPLETED ·Phase: PHASE1